News Archives

Glox Therapeutics Strengthens Team Appointing Dr Michael Murray as Chair and Dr Nel Moore as Scientific Advisory Board Member

February 11, 2025/in News, Press Release/by duncanweddell@gmail.com

Expanded team to support development and commercialisation of precision antibiotics to help overcome antimicrobial resistance

Glasgow, UK, 11 February 2025: Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced the appointment of Dr Michael Murray as Chair of the Board. He will work with the team to accelerate the company’s growth and help guide the commercialisation of its technology. The company has also expanded its scientific advisory board (SAB), adding Dr Nel Moore to support the development of its novel engineered protein bacteriocins to target drug-resistant pathogenic bacteria and help overcome antimicrobial resistance (AMR).

Dr Michael Murray is the Principal at Murray International Partners who has led multiple high-value international deals in the life sciences sector using his scientific expertise and skills in intellectual property management, market assessment, and deal making to support universities, start-ups, SMEs, mid-cap companies, and multinationals. He has nearly 30 years’ experience in senior and interim management roles at several biotech/pharma companies, including Metallobio, Porton Biopharma, EnteroBiotix, Sosei Heptares, and Amura Therapeutics, as well as an international commercial consultancy practice. He teaches commercial IP strategy on the Novo Nordisk Fellowship MBA in BioMedical Design programme (Denmark) and has delivered training to over 1,200 individuals in the commercialisation of technical innovations since 2015. Dr Murray is also a Member of The Royal Society Industry College, an Entrepreneur in Residence at the University of Sheffield, where he was a Royal Society Entrepreneur in Residence from 2019–2022, a Mentor at Cambridge Enterprise and, from 2017 until last year, was a Member of both the Research Strategy Board and the Commercialisation Committee of Coeliac UK. He is also a Registered Technology Transfer Professional and a Member of the International Technology Transfer Network (China). Dr Murray holds a PhD in Molecular Cell Biology from the University of Leicester.

Dr Nel Moore has gained vast expertise in global drug discovery, development and commercialisation in the areas of immunology, oncology and anti-infectives throughout her 21-year career in the pharmaceutical industry. Formerly, Vice President of Antibiotics Development at AstraZeneca, Dr Moore led the late-stage development, global regulatory submission and approval of Zavicefta™/Avycaz™ for the treatment of multidrug-resistant bacterial infections. She went on to build and lead AstraZeneca’s antibiotics development organisation, supporting four antibiotics in various stages of development and commercialisation, before its divestment to Pfizer. Since 2018, she has been supporting biotech companies with strategic planning, implementation and execution of business plans, and fundraising in her role as a senior R&D consultant at FWEast and non-executive director. She is currently, also an Independent Council Member at Aston University and Executive Chair/CEO of CHAIN Biotechnology. Dr Moore holds a PhD in Biochemistry from the University of Birmingham and currently sits on several CARB-X Advisory Boards.

Dr Moore joins Glox Therapeutics’ SAB led by Prof Christoph Tang FMedSci, Professor of Cellular Pathology, Sir William Dunn School of Pathology, University of Oxford alongside: Prof Colin Kleanthous FMedSci, Co-founder of Glox Therapeutics and the Iveagh Professor of Microbial Biochemistry, University of Oxford; Prof Derrick Crook, Consultant Physician in Infectious Diseases and Clinical Microbiology, Oxford University Hospital, NHS, Foundation Trust and Professor of Microbiology, Nuffield Department of Medicine, University of Oxford; Dr Michael Steward, a biopharmaceutical drug discovery scientist with more than 25 years in leadership positions within molecular biology/protein biochemistry research in the academic, biotech and pharmaceutical sectors; and Prof Gerhard Winter, Chair of Pharmaceutical Technology and Biopharmacy, Department Pharmacy at Ludwig Maximilian University of Munich.

Dr James Clark, CEO and Co-founder, Glox Therapeutics, said: “Drs Murray and Moore have an outstanding track record in their respective fields. We are delighted to welcome both of these eminent individuals on board as we continue to drive expansion and strengthen our team. Their commercial expertise and unique research perspectives will be an invaluable strategic resource as we stride towards our goal to create potent, species-specific antibiotics that combat AMR.”

Dr Michael Murray, Chair, Glox Therapeutics, said: “It’s a thrilling time to be joining the Board following the company’s successful seed funding round and PACE and CF AMR Syndicate grants. The exemplary team at Glox Therapeutics and the calibre of science behind its pioneering platform are set to transform the management of AMR infections. I’m excited to help the company grow and continue to progress its therapeutic programme to unlock the incredible potential of this technology.”

Dr Nel Moore, SAB Member, Glox Therapeutics, said: “Glox Therapeutics’ engineered protein bacteriocins represent an entirely new class of therapeutic antibiotics to target pathogenic bacteria related to AMR, helping to address the current shortcomings in this field. I very much look forward to working closely with their highly accomplished team to prevent and treat bacterial infections that pose a major threat to global human health.”

For further information about Glox Therapeutics’ team, please visit: https://gloxtherapeutics.com/about/

ENDS

Notes to Editors

Dr James Clark, CEO and Co-founder, Glox Therapeutics

Dr Michael Murray, Chair, Glox Therapeutics

Dr Nel Moore, SAB Member, Glox Therapeutics

Please contact Codon Communications for high-resolution images.

Glox Therapeutics

Dr James Clark

Email: info@gloxtherapeutics.com

Codon Communications

Dr Michelle Ricketts

Tel: +447789053885

Email: michelle.ricketts@codoncommunications.com

If you no longer wish to receive press releases from Codon Communications, please contact hello@codoncommunications.com. Click here to view our privacy policy.

About Glox Therapeutics www.gloxtherapeutics.com

Glox Therapeutics is developing a pipeline of engineered precision bacteriocins targeting pathogens that cause serious infections associated with high levels of antimicrobial resistance (AMR) and mortality. These novel precision antibiotics have potent narrow-spectrum activity to target Gram-negative AMR pathogens without collateral damage to the wider human microbiome.

Founded in 2023, the Company is built out of over 20 years of research at the Universities of Glasgow and Oxford from globally recognised expertise in elucidating bacteriocin structure and function to treat bacterial infections. It is uniquely positioned to address the AMR public health crisis which is predicted to surpass 10 million deaths globally per year at a cost of $100 trillion dollars by 2050.

The company is supported by a highly expert network of scientific advisers and has received investment and support from high-profile investors, the Boehringer Ingelheim Venture Fund and Scottish Enterprise, as well as grant funding from PACE and the CF AMR Syndicate.

Follow Glox Therapeutics on LinkedIn GLOX Therapeutics Ltd. and X (Twitter) @GloxThera

Glox Therapeutics Awarded Share of £3M Collaborative Discovery Programme Funding from Cystic Fibrosis Antimicrobial Resistance Syndicate

January 21, 2025/in News, Press Release/by duncanweddell@gmail.com

£500K grant to advance discovery and development of effective precision antibiotics targeting antimicrobial-resistant lung infections in people with cystic fibrosis
Programme delivered by CF AMR Syndicate offers cross-sector collaboration and support to address urgent unmet need

Glasgow, UK, 21 January 2025: Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has been awarded a share of the £3 million Collaborative Discovery Programme (CDP) launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate with funding from the medical research charity, LifeArc. Glox Therapeutics will receive up to £500,000 of the fund to accelerate the development of its novel precision antibiotics, helping to address the growing need for effective treatments to overcome antimicrobial-resistant lung infections in people with cystic fibrosis (CF).

Over 162,000+ people are estimated to be living with CF globally*. The thick mucus that lines the lungs of people with CF can be difficult to clear, often resulting in infections due to pathogens, such as Pseudomonas aeruginosa, becoming embedded. This typically requires antibiotic treatment; however, the bacteria may become resistant to antibiotics over time, leading to antimicrobial resistance (AMR).

Glox Therapeutics’ proprietary protein bacteriocin engineering platform allows for the development of potent therapeutics that selectively eradicate drug-resistant pathogenic bacteria. These novel antibiotics do so without damaging the human microbiome, offering efficacious therapies to treat infections associated with CF.

The CDP is led by the CF AMR Syndicate, a cross-sector initiative driven by Medicines Discovery Catapult, LifeArc and Cystic Fibrosis Trust. The CF AMR Syndicate combines the expertise of leaders in CF and AMR from industry, academia and the clinic, with insights from people living with CF to accelerate CF antimicrobial drug discovery and development. This collaborative approach will allow Glox Therapeutics to benefit from expert support and resources to expedite the discovery and development of new and effective treatment options for people with CF lung infections.

Dr James Clark, CEO and Co-founder, Glox Therapeutics, said: “There is a critical need for new and effective therapeutics to tackle the rise of antimicrobial-resistant lung infections in people with CF. We are grateful to LifeArc for the CDP funding, recognising the potential of Glox Therapeutics’ unique platform to address this urgent unmet need. The collaborative support, disease insights and expert guidance of the CF AMR Syndicate will be incredibly valuable as we advance the development of our precision antibiotics to help improve the lives of patients.”

Dr Catherine Kettleborough, Head of Chronic Respiratory Infection Translational Challenge, LifeArc, said: “Collaboration is essential to unlocking new avenues in drug discovery, especially in areas like CF where AMR poses such significant challenges. Funding research through the CF AMR Syndicate will play a crucial role in catalysing scientific progress, and we’re thrilled to support Glox Therapeutics in their work.”

Dr Beverley Isherwood, Strategy Leader, Infectious Diseases, Medicines Discovery Catapult, said: “We are delighted to be working with innovative companies like Glox Therapeutics to accelerate vital research and find new treatments for people with CF. By supporting awardees through the early development phases to generate essential data packages, the CF AMR Syndicate’s CDP will position these projects to attract onward funding and investment for further development.”

Dr Paula Sommer, Head of Research and Partnerships, Cystic Fibrosis Trust, said: “For people with CF, lung infections can cause major disruptions to day-to-day life and may lead to permanent lung damage. These infections are hard to treat due to AMR, which is why we’re delighted to see the CF AMR Syndicate support these projects that will develop urgently needed new antimicrobial treatments for CF.”

For further information about Glox Therapeutics’ precision antibiotics, please visit: https://gloxtherapeutics.com/platform/

For details of the CF AMR Syndicate’s CDP, please visit: https://cfamr.org.uk/collaborative-discovery-programme/

*Worldwide rates of diagnosis and effective treatment for cystic fibrosis (J Cyst Fibros, 2022)

ENDS

Dr James Clark, CEO and Co-founder, Glox Therapeutics

Dr Catherine Kettleborough, Head of Chronic Respiratory Infection Translational Challenge, LifeArc

Dr Beverley Isherwood, Programme Director, PACE

Dr Paula Sommer, Head of Research and Partnerships, Cystic Fibrosis Trust

Glox Therapeutics Awarded £1M PACE Grant to Accelerate Development of Precision Antibiotics Against Antimicrobial-resistant Pathogens

November 20, 2024/in News, Press Release/by duncanweddell@gmail.com

Novel therapeutics to address unmet clinical need for pneumonias caused by drug-resistant Escherichia coli and Klebsiella pneumoniae
PACE provides funding and support for innovative, high value, high risk, early phase drug discovery and diagnostic projects

Glasgow, UK, 20th November 2024: Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has secured £1 million in grant funding from PACE (Pathways to Antimicrobial Clinical Efficacy), one of the UK’s largest public-private initiatives targeting early-stage antimicrobial medicines and diagnostic discovery. The funding will help to accelerate the development of Glox Therapeutics’ novel antibiotics targeting drug-resistant pathogenic bacteria, Escherichia coli and Klebsiella pneumoniae. It will also enable the company to expand its team and foster further collaboration with industry experts.

Glox Therapeutics is developing an entirely new class of antimicrobials based on proprietary protein bacteriocin engineering platforms. These potent therapeutics target speciﬁc pathogens, or a closely related group of pathogens, to selectively eradicate drug-resistant bacteria with unprecedented efficacy. Unlike conventional antibiotics, these do not harm the human microbiome, ensuring a more effective treatment strategy with reduced side-effects.

PACE has awarded Glox Therapeutics £1 million to further the development of its narrow-spectrum antibiotics targeted at E. coli and K. pneumoniae. These frequently multidrug-resistant pathogens are a major cause of serious conditions, such as pneumonia, blood stream infections and recurrent urinary tract infections, and are associated with high levels of antimicrobial resistance (AMR)-related mortality. The initial focus will be on hospital- and ventilator-associated pneumonias.

PACE was founded in 2023 by LifeArc, Medicines Discovery Catapult, and Innovate UK with a £30 million programme of funding and support to be deployed over five years. It seeks to fund and support global AMR innovators with the best science. Projects in the PACE portfolio receive funding and additional support, including R&D advice and access to a UK network of delivery partners, to drive the projects forward for onward investment and ultimately closer to clinical impact.

Dr James Clark, CEO and Co-founder, Glox Therapeutics, said: “We are grateful to PACE for their support and recognising the groundbreaking potential of our unique technology. Glox Therapeutics is one of only a handful of companies to have been selected for PACE funding so far which is a true testament to the expertise of our world-leading team.
“AMR poses a significant threat to human health globally and this grant will enable us to expand our team and progress the development of our innovative engineered bacteriocins to help combat two of the most life-threatening pathogens.”

Dr Beverley Isherwood, Programme Director, PACE, said: “We are delighted to welcome Glox Therapeutics into the first cohort of PACE-funded projects with their novel platform to develop precision antibiotics. Using a collaborative approach, PACE will support Glox Therapeutics to generate the essential data packages needed to position the project for onward funding, investment and development.”

Kerry Sharp, Director of Entrepreneurship and Investment, Scottish Enterprise, and Investor, Glox Therapeutics, said: “This latest PACE funding for Glox Therapeutics is a massive boost to the business who are operating in such a critical development area. At Scottish Enterprise, one of our aims is to double the number of scaling businesses, which will lead to more high value jobs supporting the transformation of the Scottish economy. This is why we’re collaborating closely with our partners, like Innovate UK, to make it easier for ambitious high growth businesses in Scotland to access the innovation support needed to grow and scale.”

For further information about Glox Therapeutics’ precision antibiotics, please visit: https://gloxtherapeutics.com/platform/

ENDS

Notes to Editors

Dr James Clark, CEO and Co-founder, Glox Therapeutics

Dr Beverley Isherwood, Programme Director, PACE

Please contact Codon Communications for high-resolution images.

Glox Therapeutics
Dr James Clark
Email: info@gloxtherapeutics.com

Codon Communications
Dr Michelle Ricketts
Tel: +447789053885
Email: michelle.ricketts@codoncommunications.com

If you no longer wish to receive press releases from Codon Communications, please contact hello@codoncommunications.com. Click here to view our privacy policy.

About Glox Therapeutics www.gloxtherapeutics.com
Glox Therapeutics is developing a pipeline of engineered precision bacteriocins targeting pathogens that cause serious infections associated with high levels of antimicrobial resistance (AMR) and mortality. These novel precision antibiotics have potent narrow-spectrum activity to target Gram-negative AMR pathogens without collateral damage to the wider human microbiome.

Founded in 2023, the company is built out of over 20 years of research at the Universities of Glasgow and Oxford from globally recognised expertise in elucidating bacteriocin structure and function to treat bacterial infections. It is uniquely positioned to address the AMR public health crisis which is predicted to surpass 10 million deaths globally per year at a cost of $100 trillion dollars by 2050.

The company is supported by a highly expert network of scientific advisers and has received investment and support from high-profile investors the Boehringer Ingelheim Venture Fund and Scottish Enterprise.

Follow Glox Therapeutics on LinkedIn GLOX Therapeutics Ltd. and X (Twitter) @GloxThera

About PACE https://paceamr.org.uk/
PACE is a new and comprehensive approach to tackling one of the world’s most complex health challenges – antimicrobial resistance (AMR). PACE works with the AMR community and offers funding, support and advice to help progress early-stage antimicrobial drug and diagnostic projects with greater speed and confidence – giving the best AMR innovations the greatest chance of success.

PACE selects, invests in and supports projects that address the world’s most threatening pathogens. In doing so, it will deliver innovations for onward development and investment, moving them closer to clinical trials. Working together with the brightest and best, PACE will help tackle this rising threat to global health.

PACE was founded in 2023 by LifeArc, Innovate UK and Medicines Discovery Catapult, with a £30 million programme of funding and support to be deployed over five years.

About Scottish Enterprise www.scottish-enterprise.com
Scottish Enterprise (SE) is Scotland’s national economic development agency and a non-departmental public body of the Scottish Government. It supports businesses to innovate and scale to transform the Scottish economy by focusing on new market opportunities through targeted investment, innovation and internationalisation.

Glox Therapeutics has been shortlisted for the @University of Glasgow Spin-out of the Year award

November 19, 2024/in News/by duncanweddell@gmail.com

Excited to announce that Glox Therapeutics has been shortlisted for the @University of Glasgow Spin-out of the Year award which highlights high-performing commercial or social enterprise spin-outs from University of Glasgow research.

This is recognition of the great team we have at Glox Therapeutics and the significant progress the company has made in developing novel precision antibiotics.

The winner will be announced at the #UofGPeopleExcellence celebration on November 21st.

Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria

November 14, 2023/in News, Press Release/by James Clark

14 November 2023

PRESS RELEASE

Investment to accelerate development of a novel class of targeted high-potency bacteriocins against specific antimicrobial-resistant pathogens
Spin-out from the Universities of Glasgow and Oxford

Funding led by Boehringer Ingelheim Venture Fund and Scottish Enterprise

Company to establish operations and expand team

Glasgow, UK, 14 November 2023: Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria. The Company will use the funding to establish laboratories in Oxford and Glasgow and expand its team to accelerate its bacteriocin development programme. The investment round was led by Boehringer Ingelheim Venture Fund and Scottish Enterprise.

Antimicrobial resistance (AMR) is a major public health crisis throughout the world. It is estimated that around 1.27 million people per year die as a result of AMR due to the therapeutic failure of available antibiotics.* By 2050, AMR is predicted to surpass 10 million deaths globally per year at a cost of $100 trillion dollars; hence, there is an urgent need to develop new effective antimicrobial therapeutics.**

Glox Therapeutics is developing precision antibiotics utilising engineered protein bacteriocins. These novel antimicrobials exhibit remarkable potency and specificity, enabling them to effectively and selectively target Gram-negative pathogens that have already developed AMR, including Pseudomonas aeruginosa and Klebsiella pneumoniae. Bacteriocins, which are naturally produced by bacteria, possess antimicrobial properties against strains of the same or related species. Leveraging the power of bacteriocins, Glox Therapeutics aims to advance the field of antimicrobial therapy by overcoming resistance to traditional antibiotics. It will focus on selectively eradicating target pathogens while preserving the patient’s microbiomes, ensuring a more balanced and effective treatment strategy with reduced side-effects.

The Company was founded in February 2023 by recognised leaders in the bacteriocin field: Prof Daniel Walker from the University of Glasgow (now at the University of Strathclyde) and Prof Colin Kleanthous, Fellow of the Academy of Medical Sciences (FMedSci), from the University of Oxford. Dr James Clark was appointed as CEO in April this year. He has been involved in precision medicine for 25 years and has extensive C-suite level experience in the development and commercialisation of diagnostic and therapeutic products at PredictImmune, EnteroBiotix, Inivata, Enterome, MDxHealth and GSK.

“Our mission is to provide physicians and patients with highly potent, targeted antimicrobial therapies that can kill antibiotic-resistant bacteria for which there are diminishing options available for treatment,” said Dr James Clark, CEO, Glox Therapeutics. “This seed funding is testament to the promise of Glox Therapeutics’ precise antibiotic therapies, and we are thrilled to have the backing of such high-calibre investors. This will enable us to establish laboratories and attract top-tier talent, and I’m delighted to lead the team as we embark on our pioneering bacteriocin development programme, with the first target being P. aeruginosa,” he added.

Uzma Khan, Vice Principal Economic Development and Innovation, University of Glasgow, said: “Bacteriocins offer the precision needed to target pathogens resistant to current treatments. Our novel platform, developed in collaboration with the University of Oxford, circumvents problems traditionally associated with using bacteriocins as therapeutics. We look forward to seeing the Company carry this forward to help deliver Gram-negative antimicrobial drugs.”

Prof Chas Bountra, Pro Vice-Chancellor for Innovation, University of Oxford, said: “There is a growing consensus that the next generation of antibiotics should be narrow-spectrum therapeutics, able to target specific pathogenic AMR bacteria without collateral damage to the wider human microbiome, which is so vital to our health and wellbeing. Glox Therapeutics’ high-potency therapies offer the long-awaited solution to address these urgent unmet medical needs in tackling treatment-resistant bacterial infections.”

Dr Niklas Czeloth, Executive Director / Investment Manager, Boehringer Ingelheim Venture Fund, said: “The Boehringer Ingelheim Venture Fund is excited to invest in Glox Therapeutics, thereby advancing the development of its ground-breaking class of bacteriocins. In a world grappling with the escalating threat of AMR, there is an urgent global need for innovative approaches that target novel mechanisms devoid of any pre-existing resistance. We firmly believe that Glox Therapeutics holds immense potential to make a profound impact in the battle against antibiotic-resistant infections.”

Kerry Sharp, Director of Entrepreneurship and Investment, Scottish Enterprise, said: “Glox Therapeutics is a fantastic example of an ambitious spin-out that’s commercialising world-class life sciences research with the potential to save lives worldwide. The calibre of Scottish early-stage companies, like Glox Therapeutics, continues to attract international investment, enabling our youngest companies to positively contribute to Scotland’s economy as they scale up.”

For more information about Glox Therapeutics, please visit: https://gloxtherapeutics.com/

* Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis (The Lancet, 2022)

** Tackling Drug-Resistant Infections Globally: final report and recommendations (The Review on Antimicrobial Resistance,ENDS

Notes to Editors

Please contact Codon Communications for high-resolution images.

Glox Therapeutics

Dr James Clark

Email: info@gloxtherapeutics.com

Codon Communications

Dr Michelle Ricketts

Tel: +447789053885

Email: michelle.ricketts@codoncommunications.com

If you no longer wish to receive press releases from Codon Communications, please contact hello@codoncommunications.com. Click here to view our privacy policy.

About Glox Therapeutics

www.gloxtherapeutics.com

Founded in 2023, the Company is built out of over 20+ years of research from globally recognised expertise in elucidating bacteriocin structure and function to treat bacterial infections. It is uniquely positioned to address the AMR public health crisis which is predicted to surpass 10 million deaths globally per year at a cost of $100 trillion dollars by 2050.

Follow Glox Therapeutics on LinkedIn GLOX Therapeutics Ltd. and X (Twitter) @GloxThera

About University of Glasgow

www.gla.ac.uk

Founded in 1451, The University of Glasgow is a world-class university, committed to working with global partners to create high-quality research with real-life impact.

We were named the Scottish University of the Year by the Times & Sunday Times Good University Guide 2024 and have been home to world-changing research and teaching for more than 570 years.

Our research excellence responds to some of the world’s greatest challenges in areas such as precision medicine and chronic diseases, one health, future life, addressing inequalities, cultural and creative economies, and the nano and quantum world.

About Oxford University Innovation

Oxford University Innovation is the research commercialisation arm of Oxford University, supporting innovation and entrepreneurial activities across all University Divisions. Our mission is to create a world-leading innovation ecosystem with Oxford University at its heart.

OUI deploys Oxford research and technology through intellectual property licensing, spinout and social venture company formation, and material sales. We provide access to academic expertise and university facilities through our Consulting Services team. Our Incubator supports the entrepreneurial ambition of University staff, students and alumni, and has created over 50 startups since 2011. OUI partners with investors through our New Venture Support & Funding team to galvanise early-stage capital for world-changing Oxford ideas. Our Clinical Outcomes team works with clinicians to improve the lives and health impact of disease for patients globally.

Oxford University Innovation is the highest university patent filer in the UK and is ranked first in the UK for university spinouts. Through OUI, the University has created over 300 companies based on innovative ideas and research coming from Oxford.

Find out more: https://innovation.ox.ac.uk/

About Oxford Science Enterprises

www.oxfordscienceenterprises.com

Oxford Science Enterprises (OSE) is an independent, billion-pound investment company, created in 2015 to found, fund and build transformational businesses via its unique partnership with the University of Oxford, the world’s #1 research university.

This partnership enables OSE to work with the brightest academic minds tackling the world’s toughest challenges and guarantees unrivalled access to their scientific research. In collaboration with its global network of entrepreneurs and advisers, OSE goes well beyond funding to shape and nurture these complex ideas into successful businesses.

Actively focused on a core portfolio of around 40 companies spanning three high-growth, high-impact sectors – Life Sciences, Health Tech, and Deep Tech – the company adopts a flexible, long-term investment approach, recognising the path from ground-breaking research to global markets takes time and resilience.

To date, OSE has invested £0.6 billion in over 80 ambitious companies built on Oxford science. A key player in Oxford’s entrepreneurial ecosystem, OSE is highly motivated to foster an environment that catalyses pioneering research and steers it to commercial success.

About Boehringer Ingelheim Venture Fund

Created in 2010, the Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in ground-breaking companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF’s focus is to target unprecedented concepts addressing high medical needs in immuno-oncology, regenerative medicine, infectious diseases and digital health. For more information, please visit: www.boehringer-ingelheim-venture.com

About Scottish Enterprise

www.scottish-enterprise.com

Scottish Enterprise (SE) is Scotland’s national economic development agency and a non-departmental public body of the Scottish Government. It supports businesses to innovate and scale to transform the Scottish economy by focusing on new market opportunities through targeted investment, innovation and internationalisation.